Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 23 of 23 entries
View as:

Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis

Phase: N/A Priority: Normal
NCT ID: NCT02345746 Org: User:
Start: 12/31/12 End: 12/31/13 Due: 12/31/14

Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01833767 Org: User:
Start: 10/31/12 End: 12/31/15 Due: 12/31/16

Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01851174 Org: User:
Start: 02/28/13 End: 01/31/15 Due: 01/31/16

Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01936961 Org: User:
Start: 06/30/13 End: 04/30/14 Due: 04/30/15

A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas

Phase: N/A Priority: Normal
NCT ID: NCT02868892 Org: User:
Start: 07/31/15 End: 07/31/17 Due: 07/31/18

Study of Branched-chain Amino Acids in Cancer Cachexia

Phase: N/A Priority: Normal
NCT ID: NCT03253029 Org: User:
Start: 04/30/15 End: 04/30/16 Due: 04/30/17

Fasting on Newly Diagnosed Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02379585 Org: User:
Start: 01/31/13 End: 08/31/15 Due: 08/31/16

Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01937507 Org: User:
Start: 12/31/12 End: 07/31/14 Due: 07/31/15

Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02318901 Org: User:
Start: 10/31/14 End: 08/31/18 Due: 08/31/19

Interleukin-2 in Metastatic Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01702909 Org: User:
Start: 09/30/12 End: 12/31/14 Due: 12/31/15

Capecitabine With Digoxin for Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01887288 Org: User:
Start: 04/30/13 End: 11/30/15 Due: 11/30/16

Interleukin-2 in Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01702896 Org: User:
Start: 09/30/12 End: 12/31/14 Due: 12/31/15

Quality of Life Assessment of Cryotherapy in Esophageal or Gastroesophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03285035 Org: User:
Start: 07/13/17 End: 01/13/21 Due: 01/13/22

Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy

Phase: N/A Priority: Normal
NCT ID: NCT02414776 Org: User:
Start: 07/31/14 End: 11/30/15 Due: 11/30/16

Dacarbazine and Carmustine in Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01692691 Org: User:
Start: 08/31/12 End: 10/31/14 Due: 10/31/15

Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01860040 Org: User:
Start: 04/30/13 End: 04/30/16 Due: 04/30/17

Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)

Phase: N/A Priority: Normal
NCT ID: NCT02423954 Org: User:
Start: 04/30/15 End: 11/01/17 Due: 11/01/18

5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01658813 Org: User:
Start: 07/31/12 End: 07/31/14 Due: 07/31/15

Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

Phase: N/A Priority: Normal
NCT ID: NCT02331251 Org: User:
Start: 12/31/14 End: 01/31/18 Due: 01/31/19

(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01936974 Org: User:
Start: 09/30/13 End: 08/31/15 Due: 08/31/16

Next-generation Sequencing of Small Cell Lung Cancer to Identify Actionable Targets for Treatment

Phase: N/A Priority: Normal
NCT ID: NCT02297087 Org: User:
Start: 10/31/14 End: 10/31/17 Due: 10/31/18

Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy

Phase: N/A Priority: Normal
NCT ID: NCT02345772 Org: User:
Start: 07/31/14 End: 11/30/15 Due: 11/30/16

Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)

Phase: N/A Priority: Normal
NCT ID: NCT02408042 Org: User:
Start: 04/30/15 End: 11/30/15 Due: 11/30/16